Literature DB >> 18794106

Familial non-VHL clear cell (conventional) renal cell carcinoma: clinical features, segregation analysis, and mutation analysis of FLCN.

Emma R Woodward1, Christopher Ricketts, Pip Killick, Sophie Gad, M R Morris, Fred Kavalier, Shirley V Hodgson, Sophie Giraud, Brigitte Bressac-de Paillerets, Cyril Chapman, Bernard Escudier, Farida Latif, Stéphane Richard, Eamonn R Maher.   

Abstract

PURPOSE: Familial renal cell carcinoma (RCC) is genetically heterogeneous. The most common histopathologic subtype of sporadic and familial RCC is clear cell (cRCC) and von Hippel-Lindau (VHL) disease is the most common cause of inherited cRCC. Familial cRCC may also be associated with chromosome 3 translocations and has recently been described in patients with Birt-Hogg-Dube (BHD) syndrome, caused by germline FLCN mutation. Fewer than 20 kindreds with familial cRCC without VHL disease or a constitutional translocation have been described. The purpose of this investigation was to define the clinical and genetic features of familial non-VHL cRCC (FcRCC) and to evaluate whether unrecognized BHD syndrome might be present in patients with apparent nonsyndromic RCC susceptibility. EXPERIMENTAL
DESIGN: We analyzed the clinical features of, and undertook segregation analysis in, 60 kindreds containing two or more cases of RCC (at least one confirmed case of cRCC) and no evidence of an RCC susceptibility syndrome. We also undertook FLCN analysis to evaluate whether unrecognized BHD syndrome might be present in 69 patients with apparent nonsyndromic RCC susceptibility.
RESULTS: FcRCC was characterized by an earlier age at onset than sporadic cases and more frequent occurrence of bilateral or multicentric tumors. Segregation analysis showed autosomal dominant inheritance with sex- and age-dependent penetrance. A germline FLCN mutation was detected in 3 of 69 (4.3%) patients with apparent nonsyndromic RCC susceptibility.
CONCLUSIONS: We describe the clinical and genetic features of the largest series of FcRCC and recommend these patients be offered FLCN analysis, in addition to constitutional cytogenetic and VHL analysis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18794106     DOI: 10.1158/1078-0432.CCR-08-0608

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  24 in total

1.  The folliculin mutation database: an online database of mutations associated with Birt-Hogg-Dubé syndrome.

Authors:  Ming-Hui Wei; Patrick W Blake; Julia Shevchenko; Jorge R Toro
Journal:  Hum Mutat       Date:  2009-09       Impact factor: 4.878

2.  Genetic screening of the FLCN gene identify six novel variants and a Danish founder mutation.

Authors:  Maria Rossing; Anders Albrechtsen; Anne-Bine Skytte; Uffe B Jensen; Lilian B Ousager; Anne-Marie Gerdes; Finn C Nielsen; Thomas vO Hansen
Journal:  J Hum Genet       Date:  2016-10-13       Impact factor: 3.172

Review 3.  Advances in the genetics of familial renal cancer.

Authors:  Patrick J Morrison; Deirdre E Donnelly; A Brew Atkinson; Alexander P Maxwell
Journal:  Oncologist       Date:  2010-05-19

Review 4.  Non-clear cell renal cell carcinoma: how new biological insight may lead to new therapeutic modalities.

Authors:  Axel Bex; James Larkin; Christian Blank
Journal:  Curr Oncol Rep       Date:  2011-06       Impact factor: 5.075

5.  Germline and somatic DNA methylation and epigenetic regulation of KILLIN in renal cell carcinoma.

Authors:  Kristi L Bennett; Rebecca Campbell; Shireen Ganapathi; Ming Zhou; Brian Rini; Ram Ganapathi; Hartmut P H Neumann; Charis Eng
Journal:  Genes Chromosomes Cancer       Date:  2011-05-16       Impact factor: 5.006

6.  Folliculin interacts with p0071 (plakophilin-4) and deficiency is associated with disordered RhoA signalling, epithelial polarization and cytokinesis.

Authors:  Michael S Nahorski; Laurence Seabra; Ania Straatman-Iwanowska; Aileen Wingenfeld; Anne Reiman; Xiaohong Lu; Jeff A Klomp; Bin T Teh; Mechthild Hatzfeld; Paul Gissen; Eamonn R Maher
Journal:  Hum Mol Genet       Date:  2012-09-10       Impact factor: 6.150

7.  Germline BAP1 mutations predispose to renal cell carcinomas.

Authors:  Tatiana Popova; Lucie Hebert; Virginie Jacquemin; Sophie Gad; Virginie Caux-Moncoutier; Catherine Dubois-d'Enghien; Bénédicte Richaudeau; Xavier Renaudin; Jason Sellers; André Nicolas; Xavier Sastre-Garau; Laurence Desjardins; Gabor Gyapay; Virginie Raynal; Olga M Sinilnikova; Nadine Andrieu; Elodie Manié; Antoine de Pauw; Paul Gesta; Valérie Bonadona; Christine M Maugard; Clotilde Penet; Marie-Françoise Avril; Emmanuel Barillot; Odile Cabaret; Olivier Delattre; Stéphane Richard; Olivier Caron; Meriem Benfodda; Hui-Han Hu; Nadem Soufir; Brigitte Bressac-de Paillerets; Dominique Stoppa-Lyonnet; Marc-Henri Stern
Journal:  Am J Hum Genet       Date:  2013-05-16       Impact factor: 11.025

Review 8.  The roles of intrinsic disorder-based liquid-liquid phase transitions in the "Dr. Jekyll-Mr. Hyde" behavior of proteins involved in amyotrophic lateral sclerosis and frontotemporal lobar degeneration.

Authors:  Vladimir N Uversky
Journal:  Autophagy       Date:  2017-12-17       Impact factor: 16.016

9.  Absence of the Birt-Hogg-Dubé gene product is associated with increased hypoxia-inducible factor transcriptional activity and a loss of metabolic flexibility.

Authors:  R S Preston; A Philp; T Claessens; L Gijezen; A B Dydensborg; E A Dunlop; K T Harper; T Brinkhuizen; F H Menko; D M Davies; S C Land; A Pause; K Baar; M A M van Steensel; A R Tee
Journal:  Oncogene       Date:  2010-11-08       Impact factor: 9.867

10.  A de novo FLCN mutation in a patient with spontaneous pneumothorax and renal cancer; a clinical and molecular evaluation.

Authors:  Fred H Menko; Paul C Johannesma; R Jeroen A van Moorselaar; Rinze Reinhard; Jan Hein van Waesberghe; Erik Thunnissen; Arjan C Houweling; Edward M Leter; Quinten Waisfisz; Martijn B van Doorn; Theo M Starink; Pieter E Postmus; Barry J Coull; Maurice A M van Steensel; Johan J P Gille
Journal:  Fam Cancer       Date:  2013-09       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.